Programmed Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor and Monitor of Response to Atezolizumab plus Bevacizumab Treatment in Patients with Hepatocellular Carcinoma DOI Open Access
Takuto Nosaka,

Yosuke Murata,

Yu Akazawa

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(9), P. 1785 - 1785

Published: May 6, 2024

There remains no reliable biomarker of therapeutic efficacy in hepatocellular carcinoma (HCC) for the PD-L1 inhibitor atezolizumab and bevacizumab (Atezo/Bev). Circulating tumor cells (CTCs) enable serial collection living cells. Pre-treatment CTC gene expression changes histology were evaluated to identify predictors response Atezo/Bev. Peripheral blood from 22 patients with HCC treated Atezo/Bev 24 lenvatinib was serially collected. The RNA CTCs analyzed using qRT-PCR. Higher pre-treatment associated improved prognosis treatment, but not lenvatinib. correlation between that liver biopsy specimens scored imaging software. Furthermore, dynamically altered by Atezo/Bev, decreasing during effective increasing upon progression. CTC-derived collected indicates higher at baseline 3.9 times more responsive treatment. Therefore, levels are an accurate predictor may be a monitorable reflect

Language: Английский

Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination DOI
Shujia Chen, Lili Zhao, Jie Liu

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217105 - 217105

Published: July 4, 2024

Language: Английский

Citations

5
SiRNA-HIF-1α delivered by attenuated Salmonella enhances the efficacy of Lenvatinib against hepatocellular carcinoma DOI
Pengfei Chen, Yanling Wang,

Xingshu Zhu

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 130, P. 111728 - 111728

Published: March 1, 2024

Language: Английский

Citations

4
Genetic Insights into Sarcomatoid Hepatocellular Carcinoma: Critical Role of ARID2 in Pathogenesis and Immune Feature DOI Creative Commons
Naoshi Nishida

Clinical and Molecular Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

sarcomatoid hepatocellular carcinoma (sHCC), conventional HCC (cHCC), tumor immune microenvironment (TME), molecular targeted agents (MTAs), checkpoint inhibitors (ICIs), epithelial-mesenchymal transition (EMT), recurrence-free survival (RFS), switch/sucrose nonfermenting (SWI/SNF), overall (OS)

Language: Английский

Citations

0
Targeted delivery of CCL3 reprograms macrophage antigen presentation and enhances the efficacy of immune checkpoint blockade therapy in hepatocellular carcinoma DOI Creative Commons
Muqi Liu, Linzhe Li, Lu Cao

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2025, Volume and Issue: 13(2), P. e010947 - e010947

Published: Feb. 1, 2025

Background Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths worldwide, especially in advanced stages where limited treatment options result poor prognosis. The immunosuppressive tumor immune microenvironment (TIME), characterized by low cell infiltration and exhaustion, limits immunotherapy efficacy. To address this, our study investigates the role C-C motif chemokine ligand 3 (CCL3) modulating HCC TIME. Methods We analyzed CCL3 expression human samples from Cancer Genome Atlas database, focusing on its correlation with inflammatory gene signatures infiltration. High-dimensional single-cell RNA sequencing (scRNA-seq), flow cytometry, multiplex immunofluorescence were used to investigate CCL3’s effects macrophage function T activation. biological impact macrophages was assessed using co-culture systems, confocal imaging, metabolite detection, inhibition assays. Preclinical models ex vivo fragment assays further explored how modulates responses enhances checkpoint blockade Results Our shows that is suppressed positively correlates responses. Targeted liver delivery rAAV-Ccl3 reprograms HCC, promoting recruitment tertiary lymphoid structure formation, thus suppressing growth via engagement. Through scRNA-seq, immunofluorescence, we found antigen uptake activates cytotoxic cells. In vitro experiments confirmed facilitates upregulates MHC II macrophages, enhancing presentation. CCL3-CCR5 pathway also boosts metabolism, increasing lysosomal activity uptake, thereby strengthening adaptive sensitivity therapies preclinical models. Conclusions This highlights pivotal reshaping TIME antitumor immunity HCC. By presentation, demonstrates significant potential improve efficacy immunotherapy, particularly combination inhibitors. Targeting may help overcome patient outcomes.

Language: Английский

Citations

0
Transforming Hepatocellular Carcinoma Treatment in Lower Income Countries DOI

Channa R. Jayasekera,

Chrishanthi Rajasooriyar,

Clayton Richards

et al.

Mayo Clinic Proceedings, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma DOI Open Access
Ping‐Ping Sun,

Haiyan Xu,

Chengfeng Guo

et al.

Liver International, Journal Year: 2025, Volume and Issue: 45(4)

Published: March 7, 2025

Transmembrane (TMEM) proteins are involved in fundamental biological processes such as material transport and signal transduction. TMEM115 is a member of the TMEM protein family, but its significance hepatocellular carcinoma (HCC) remains unclear. In this study, we investigate clinical predictive potential functions HCC. Bioinformatics was used to mRNA expression immune infiltration score. Through multiplex immunohistochemistry analysis, assessed association with HCC patient features, prognosis cell vitro vivo experiments, evaluated cells impact on microenvironment. levels were significantly higher tissues compared paracancerous liver tissues. Its correlated characteristics overall survival patients. tissues, corresponded lower proportions CD66b+ neutrophils CD8+ T proportion CD4+ cells. Furthermore, patients low displayed programmed death ligand-1 lymphocyte activation gene 3 expression. Functionally, knockdown inhibited proliferation, migration invasion orthotopic models, growth affected Our findings show promising prognostic indicator for hold promise predicting responses therapy, emphasising relevance intricate involvement microenvironment

Language: Английский

Citations

0
Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances DOI

Piotr Starnawski,

Klaudia Nowak,

Zuzanna Augustyn

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 17, 2025

Language: Английский

Citations

0
Hafnium Metal–Organic Framework-Based Glutamine Metabolism Disruptor For Potentiating Radio-Immunotherapy in MYC-Amplified Hepatocellular Carcinoma DOI

Haofan Hu,

Shangwu Ning,

Furong Liu

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Hepatocellular carcinoma (HCC) with MYC oncogene amplification remains a serious challenge in clinical practice. Recent advances comprehensive treatment strategies, particularly the combination of radiotherapy and immunotherapy, offer new hope. To further improve efficacy while lowering radiation doses, nanopharmaceuticals based on high-Z elements have been extensively studied radio-immunotherapy. In this work, hafnium-based metal-organic framework (Hf-MOF), UiO-66-Hf(2OH)-CB-839/BSO@HA (UiO-66-Hf(2OH)-C/B@HA), was designed to codeliver telaglenastat (CB-839) buthionine sulfoximine (BSO), which synergistically inhibited glutamine metabolism alleviated tumor hypoxia. Further modification hyaluronic acid (HA) enhanced targeting, ultimately strengthening MYC-amplified HCC. Beyond increasing reactive oxygen species (ROS) generation, promoting DNA damage, inducing apoptosis, more importantly, UiO66-Hf(2OH)-C/B@HA triggered immunogenic cell death (ICD), driving antitumor immune response. Combination checkpoint blockade (ICB) efficacy, accompanied by increased infiltration T cells high granzyme B expression (GZMB+ cells) within microenvironment (TME). orthotopic HCC model, established cells, intravenous administration significantly potentiated radio-immunotherapy, resulting superior regression. summary, our study provides insights into design Hf-MOF for radio-immunotherapy proposes promising therapeutic approach

Language: Английский

Citations

0
Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models DOI Creative Commons
Romain Désert,

Fabio Gianonne,

Antonio Saviano

et al.

npj gut and liver., Journal Year: 2025, Volume and Issue: 2(1)

Published: April 3, 2025

Language: Английский

Citations

0
A bibliometric and visual analysis based on immune checkpoint inhibitors for hepatocellular carcinoma: 2014 – 2024 DOI Creative Commons
Gao‐Min Liu, Rui Guo, Jiwei Xu

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 7, 2025

Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of hepatocellular carcinoma (HCC), especially those with unresectable advanced stages. The field has progressed rapidly, and research hotspots significantly compared to previous years. study aims comprehensively review analyze development history, knowledge structure, current focus, emerging trends in ICIs for HCC. Reviews articles published English from Web Science Core Collection (WoSCC) database 2014 2024 were systemically retrieved. Citespace, VOSviewer, Bibliometrix R package used further bibliometric analysis visualization countries, institutions, authors, references, keywords. 2,941 records included analysis. literature on HCC continued grow steadily over past decade. Three major centers emerged: North America, Europe, East Asia. Chinese institution highest publication volume, but Kudo Masatoshi Japan number publications. At same time, Richard S. Finn United States leads citations co-citations. most prolific journal is "Cancers". clustering Timeline view critical keywords indicated that rapidly advancing toward a more evidence-based, personalized, multimodal approach. evasion mechanisms, predictive biomarkers, high-quality clinical trials focusing Novel combination, conversion, perioperative therapies, including ICIs, are hotspots. This highlights groundbreaking advancements treating shows trend towards updated understanding identified vital future directions research, such as exploration mechanisms immune evasion, developing combining therapy strategies.

Language: Английский

Citations

0